Bright Uro Announces $23M Series A Funding Round Led by Laborie – Expands Senior Leadership Team to Accelerate Next Phase of Commercialization
Company Names Chief Product Development Officer and Chief Commercial Officer as Glean continues to progress to regulatory clearance
IRVINE, Calif.–(BUSINESS WIRE)–Bright Uro, a medical device company with a mission to transform care for lower urinary tract symptoms (LUTS) through innovations in urodynamics, today announced the initial closing of its $23M Series A financing round led by Laborie Medical Technologies, a leading global provider of urology diagnostic and therapeutic solutions. The Series A funding round includes investment from Laborie and other existing investors in the Company. Funding will be used to achieve FDA 510(k) clearance of the Glean™ Urodynamics System (Glean) and launch the product in the U.S. in 2024. Glean is a comprehensive system that enables wireless, catheter-free urodynamics and aims to revolutionize the testing process by giving clinicians more accurate data with actionable insight to aid in clinical decision-making.
